Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection

Journal of Surgical Research

Volumn 173, Issue 2, 2012, Pages 299-308

  Yamamoto, Tomohisa ^a   Yanagimoto, Hiroaki ^a   Satoi, Sohei ^a   Toyokawa, Hideyoshi ^a   Yamao, Jun ^a   Kim, Songtae ^a   Terakawa, Naoyoshi ^a   Takahashi, Kanji ^a   Kwon, A Hon ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

DC in the pancreatic cancer tissue; distribution of DC in the human body; survival analysis

Indexed keywords

FASCIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MYELOID DENDRITIC CELL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84858289306     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.09.027     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225.
2. Hirohashi S, Sobue T, Katanoda K, et al. Cancer statistics in Japan: Foundation for promotion of cancer research 2007. Tokyo: Japan, 2009:12.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403.
4. P. Neuhaus, H. Riess, S. Post. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). May 30-Jun 3, Chicago, IL. 2008 ASCO Annual Meeting.
5. Satoi S, Yanagimoto H, Toyokawa H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009;38:282.
6. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:3496.
7. Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009;250:88.
8. Yanagmoto H, Satoi S, Mine T, et al. A multicenter phase I/II study of gemcitabine and personalized peptide vaccination combination therapy for metastatic pancreatic cancer patients. May 30-Jun 3, Chicago, IL. 2008 ASCO Annual Meeting.
9. Yanagimoto H, Mine T, Yamamoto K, et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007;98:605 [Epub 2007 Feb 19].
10. Uggeri F, Caprotti R, De Grate L, et al. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: A randomized study. Hepatogastroenterology 2009;56:861.
11. von Bernstorff W, Voss M, Freichel S, Schmid A, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925.
12. Chen L, Ashe S, Brady WA, et al. Co-stimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093.
13. Zheng P, Sarma S, Guo Y, et al. Two mechanisms for tumor evasion of pre-existing cytotoxic T-cell responses: Lessons from recurrent tumors. Cancer Res 1999;59:3461.
14. Avigan D. Dendritic cells: Development, function, and potential use for cancer immunotherapy. Blood Rev 1999;13:51.
15. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767.
16. Hart DNJ. Dendritic cells: Unique leukocyte populations that control the primary immune response. Blood 1997;90:3245.
17. Ito T, Inaba M, Inaba K, et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. Immunol 1999;163:1409.
18. Steven DR, Giuseppe P, Luciano A, et al. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000; 12:114.
19. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487.
20. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immun 1991;9:271.
21. Yanagimoto H, Takai S, Satoi S, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 2005;114:52.
22. Takahashi K, Toyokawa H, Takai S, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother 2006;55:775.
23. UICC TNM Classification of Malignant Tumors. In: Sobin L, Wittekind C, Eds. 6th ed., New York: Wiley-Liss, 2002.
24. Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2002;104:92.
25. Sandel MH, Dadabayev AR, Menon AG. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576.
26. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989;63:496.
27. Edwards RA, Bryan J. Fascins, a family of actin bundling proteins. Cell Motil Cytoskel 1995;32:1.
28. Al-Alwan MM, Rowden G, Lee TD, West KA. Fascin is involved in the antigen presentation activity of mature dendritic cells. J Immunol 2001;166:338.
29. Ozaki Y, Amakawa R, Ito T, et al. Alteration of peripheral blood dendritic cells in patients with primary Sjogren's syndrome. Arthritis Rheum 2001;44:419.
30. Ota M, Amakawa R, Uehira K, et al. Involvement of dendritic cells in sarcoidosis. Thorax 2004;59:408.
31. Nozoe T, Korenaga D, Ohga T, et al. Suppression of the phytohemagglutinin response to lymphocytes is an independent prognosticator in patients with squamous cell carcinoma of the esophagus. Ann Thorac Surg 2003;76:260.
32. Farinas MC, Rodriguez-Valverde V, Zarrabeitia MT, et al. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer. Cancer 1991;68:1279.
33. Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003;33:119.